Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer: results of the randomized phase II PRODIGE 61—FUNGEMAX trial (France)
Julien Taieb, Simon Pernot, Frédéric Thuillier, A Delattre et autres